The influence of TNF alpha -308 G/A polymorphism on oxidative stress in patients with chronic lymphocytic leukemia

Jevtović-Stoimenov, Tatjana; Cvetković, Tatjana; Despotović, Milena; Bašić, Jelena; Cvetkovic, Jasmina Trifunovic; Marjanović, Goran; Pavlović, Dušica

doi:10.1016/j.leukres.2017.01.018

Cited by 9 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TNF‐α rs1800629, IL‐10 rs1800872, and IL‐10 rs1800896 SNPs were not risk factors for AML development in our population, with similar findings being reported by Pehlivan et al Similarly, a meta‐analysis of 19 publications comprising 1509 patients with leukemia and 4075 controls found no association between the TNF‐α rs1800629 polymorphism and leukemia risk . In contrast, a recent study showed statistically significant differences regarding the genotype and allele distribution of TNF‐α rs1800629 in CLL patients compared to controls ( P = .00003 and P = .00007) …”

Section: Discussionsupporting

confidence: 89%

“…29 In contrast, a recent study showed statistically significant differences regarding the genotype and allele distribution of TNF-α rs1800629 in CLL patients compared to controls (P = .00003 and P = .00007). 30 In addition, our findings indicated that TNF-α rs361525 did not confer susceptibility to AML in the additive and dominant models. No studies are currently available regarding the role of rs361525 in AML susceptibility, however, a closely-related hematological malignancy case-control study (123 Brazilian patients with MPN and 123 healthy subjects) showed that the rs361525 and rs1800629 variant genotypes were significantly higher in MPN cases (P = .04 and P = .02), providing a risk factor for developing MPN of 2.21 and 1.82, respectively.…”

Section: Discussionmentioning

confidence: 64%

See 1 more Smart Citation

Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

Background Cytokines were correlated with survival and disease progression in acute myeloid leukemia (AML). We aimed to evaluate the multivariate effect of TNF‐α rs361525, rs1800750, rs1800629, IL‐10 rs1800896, rs1800872, IL‐6 rs1800795, TGF‐β1 rs1800470, IFN‐γ rs2430561 single nucleotide polymorphisms (SNPs) on AML risk, the multivariate effect of SNPs on overall survival (OS) in AML and the association between the investigated SNPs and prognostic factors in AML. Methods All SNPs were genotyped in 226 adult AML cases and 406 healthy individuals. AML patients were investigated for FLT3 (ITD, D835), DNMT3A (R882), and NPM1 type A mutations. Results Univariate analysis revealed that age above 65 years had a negative influence on survival (P < .001). The presence of the rs1800750 variant genotype (P = .005) or FLT3‐ITD mutation (P = .009) in a cytogenetic high‐risk group (P = .003) negatively influenced OS. A negative association was observed between Eastern Cooperative Oncologic Group Scale status > 2, lactate dehydrogenase (LDH) level, platelet (PLT) count <40 000 cells/mm3, and OS. Multivariate Cox regression analysis showed that the presence of the rs1800750 variant genotype was a risk factor for death (P = .007), and that blast percentage, LDH level (≥600 IU/L), and cytogenetic high‐risk were independent significant predictors for death in AML (P = .04, corrected HR = 1.20; P = .022, corrected HR = 1.24; P = .021, corrected HR = 1.34, respectively). Conclusions Age above 65 years, PLT count, TNF‐α rs1800750 variant genotype, blast percentage, LDH level, and cytogenetic high‐risk may be used as independent risk factors to assess AML mortality.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 64%

Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Also TNF-α triggers several neutrophils functions, including oxidative burst [34]. We found a similar TNF-α plasma levels in CLL and HC at each time points analyzed (Fig.…”

Section: Ibrutinib Therapy Altered Il-8 Plasma Levels Following E Coli Stimulation But Not Affect Tnf-α Plasma Levelssupporting

confidence: 69%

Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment

et al. 2019

View full text Add to dashboard Cite

Ibrutinib is a tyrosine kinase inhibitor used in the treatment of a variety of lymphoid malignancies, including chronic lymphocytic leukemia (CLL). Drugs inhibiting B-cell-receptor (BCR)-associated kinases, including BTK inhibitors, act on B cells and on a wide spectrum of tissues and cells, including innate immunity cells. Thus, alterations in the Bruton's tyrosine kinase (BTK) kinase function could lead to an impairment of innate immune cells functions and to an increased infectious risk in patients receiving BTK inhibitors. We analyzed in vivo neutrophils oxidative burst, neutrophils granules release and cytokine production in relapsed/refractory CLL patients treated over time with ibrutinib as single-agent. We observed a dramatic reduction of neutrophils oxidative burst, Fc gamma receptors (FcγRs)-mediated degranulation and IL-8 plasma levels already after the first forty-eight hours of therapy with ibrutinib. However, ibrutinib treatment did not alter the surface expression of CD11b nor cytokine and proteinases release not mediated by FcγRs engagement. After three weeks, oxidative burst was still impaired, while degranulation and IL-8 levels were restored. In a group of CLL patients who survived for more than three years, all processes triggered by FcγRs completely recovered except the release of neutrophil elastase (NE) and IL-8. In conclusion, during the initial phases of ibrutinib therapy, the reduction of IL-8, NE, myeloperoxidase (MPO) levels and oxidative burst negatively impacted on mechanisms involved in neutrophils microbicidal activity.

show abstract

“…The association of polymorphisms genotypes with cells functions has been proved in patients with B-CLL [ 25 ]. We hypothesized that SNPs in angiogenesis pathway genes could modify B-CLL risk.…”

Section: Introductionmentioning

confidence: 99%

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Ballester

Pineda

Rodrigues

et al. 2020

Genes

View full text Add to dashboard Cite

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors genetic variants in the predisposition to B-CLL and their association with clinical factors and survival. We performed a population-based case-control study in 224 Spanish B-CLL patients and 476 healthy randomly selected controls to evaluate susceptibility to developing B-CLL. Six polymorphisms were evaluated: rs1109324, rs1547651, rs3025039 (+936 C>T), rs833052 of the VEGFA gene, rs1449683 (c.233C>T) of the bFGF gene and (−710 C>T) of the VEGFR1 gene. The association between clinical parameters and patient outcome was analyzed. Carriers of the CT/TT variants of rs3025039 showed a significant protective effect against developing B-CLL. The CT/TT variants of rs1449683 show a tendency towards the development of the disease and the same variants associated significantly with higher genetic risk and with reduced disease free survival. Moreover, the association persisted in the early-stage disease subgroup. Our study provides evidence of the protective effect of the T/- rs3025039 VEGFA variant against B-CLL development and the association of CT/TT variants of the rs1449683 bFGF gene with genetic risk and an adverse survival.

show abstract

The influence of TNF alpha -308 G/A polymorphism on oxidative stress in patients with chronic lymphocytic leukemia

Cited by 9 publications

References 35 publications

Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia

Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia

Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Contact Info

Product

Resources

About